Atlas Trials

A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

Clinical trial NCT05539248 · UNKNOWN

Trial details

NCT number
NCT05539248
Sponsor
CARE Pharma Shanghai Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
PNHHemolysis
Start date
2022-03-25
Primary completion
2024-12-01
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.